A Study of SI-B003 or BL-B01D1+SI-B003 in Patients With Unresectable Locally Advanced or Recurrent Metastatic HER2 Negative Breast Cancer

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 12, 2023

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2027

Conditions

Breast Cancer

Interventions

DRUG

BL-B01D1

BL-B01D1 was administered by intravenous infusion on D1 and D8 in a 3-week cycle.

DRUG

SI-B003

SI-B003 was administered by intravenous infusion on D1 in a 3-week cycle.

Trial Locations (1)

RECRUITING

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors

lead

Sichuan Baili Pharmaceutical Co., Ltd.

INDUSTRY